Genomic Landscape of NSCLC in the Republic of Ireland.

INTRODUCTION

The identification of genomic "targets" through next-generation sequencing (NGS) of patient's NSCLC tumors has resulted in a rapid expansion of targeted treatment options for selected patients. This retrospective study aims to identify the proportion of patients with advanced NSCLC in the Republic of Ireland whose tumors harbor actionable genomic alterations through broad NGS panel testing.

METHODS

Institutional review board approval was obtained before study initiation. Patients with NSCLC whose tumors underwent genomic testing through the largest available NGS panel at a nationally funded Cancer Molecular Diagnostics laboratory (St. James's Hospital) between June 2017 and June 2022 were identified. Patient demographics and tumor-related data were collected by retrospective review from all cancer centers in Ireland, referring to the Cancer Molecular Diagnostics laboratory. A total of 203 (9%) tumor samples were excluded due to insufficient neoplastic cell content. Genomic data were collected through retrospective search of Ion Reporter software. The spectrum and proportion of patients with oncogenic driver mutations were evaluated using descriptive statistics (SPSS version 29.0).

RESULTS

In total, 2052 patients were identified. Patients were referred from 23 different hospital sites and all four geographic regions (Leinster = 1091, 53%; Munster = 763, 37.2%; Connacht = 191, 9.3%; Ulster = 7, 0.3%). Median age was 69 (range: 26-94) years; 53% were male. The most common tumor histologic subtype was adenocarcinoma (77%, n = 1577). An actionable genomic alteration was identified in 1099 cases (53%), the most common of which was (n = 657, 32%). Less frequently, NSCLC tumors harbored the following: exon 14 skipping (n = 53, 2.6%), amplification (n = 26, 1.3%), (n = 181, 8.8%), (n = 35, 1.7%), and  (n = 72, 3.5%) mutations. Fusions were detected in 76 patients (3.7%) including (n = 44, 58%), (n = 11, 14.5%), (n = 16, 21%), and (n = 5, 6.6%), whereas no fusion was identified. Co-alterations were detected in 114 patients (5.6%), the most common of which was / (n = 19, 17%), (n = 10, 8.5%), and (n = 9, 8%). Other co-alterations of interest identified included fusion (n = 1) and (n = 2).

CONCLUSIONS

This is the first retrospective study to comprehensively characterize the genomic landscape of NSCLC in Ireland, using the broadest available NGS panel. Actionable alterations were identified in 53.4% of the patients, and was the most common oncogenic driver alteration. Our study revealed a lower prevalence of patients whose tumor harbors , , and fusions, compared with similar data sets.